Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma after Previous Platinum-Based Chemotherapy for Metastatic Disease.

Date publication

août 2021

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Dr LADOIRE Sylvain

Tous les auteurs :
Wong RL, Ferris LA, Do OA, Holt SK, Ramos JD, Crabb SJ, Sternberg CN, Bellmunt J, Ladoire S, De Giorgi U, Harshman LC, Vaishampayan UN, Necchi A, Srinivas S, Pal SK, Niegisch G, Dorff TB, Galsky MD, Yu EY

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34355457

Résumé

Fit patients with metastatic urothelial carcinoma (mUC) receive first-line platinum-based combination chemotherapy (fPBC) as standard of care and may receive additional later-line chemotherapy after progression. Our study compares outcomes with subsequent platinum-based chemotherapy (sPBC) versus subsequent non-platinum-based chemotherapy (sNPBC).

Mots clés

Antineoplastic agents, Cisplatin, carboplatin, Drug therapy, combination, Platinum compounds, Urinary bladder neoplasms, Urologic neoplasms

Référence

Oncologist. 2021 Aug 6;: